Literature DB >> 22896786

Cytoplasmic superoxide radical: a possible contributing factor to intracellular Aβ oligomerization in Alzheimer disease.

Kazuma Murakami, Takahiko Shimizu.   

Abstract

Soluble amyloid β (Aβ) oligomers cause memory loss and synaptic dysfunction in Alzheimer disease (AD). Despite intensive studies on Aβ assembly in vitro and in vivo, the localization and cellular mechanism of Aβ oligomerization are not fully understood. Previously, we demonstrated that cytoplasmic superoxide radicals contribute to drusen deposition, a hallmark of age-related macular degeneration as well as other geriatric diseases (fatty liver, skin thinning, and osteoporosis). Using a transgenic mouse model of AD, we recently clarified the role of cytoplasmic oxidative stress in cognitive impairment and oligomer formation. Moreover, we also found that these phenomena were associated with neuroinflammation, tau phosphorylation, and synaptic loss. Notably, studies using human brains support the involvement of cytoplasmic superoxide radicals in AD pathology. In this addendum to Murakami et al. (JBC 2011), we discuss and comment on intracellular Aβ oligomer formation and the possible therapeutic effects of intracellular redox state modulators.

Entities:  

Keywords:  Alzheimer’s disease; SOD; amyloid β; memory loss; oligomer; oxidative stress; superoxide radical

Year:  2012        PMID: 22896786      PMCID: PMC3419108          DOI: 10.4161/cib.19548

Source DB:  PubMed          Journal:  Commun Integr Biol        ISSN: 1942-0889


Alzheimer disease (AD) is characterized by the presence of senile plaques that mainly contain 40- and 42-mer amyloid β-proteins (Aβ40, Aβ42)., These proteins are generated from amyloid β-protein precursor by β-site hAPP-cleaving enzyme 1 (BACE1), followed by γ-secretase processing (the amyloidogenic pathway). Many studies have demonstrated that soluble Aβ oligomers (50~60 kDa: Aβ-derived diffusible ligands, Aβ*56, and globulomers; > 100 kDa: amylospheroid, protofibrils, and annuli) rather than insoluble fibrils cause memory loss and synaptic dysfunction. Oxidative stress contributes to the pathogenesis of several neurodegenerative diseases, such as AD, Parkinson disease, and amyotrophic lateral sclerosis., In addition, a study that detected the in vitro radicalization of Aβ suggested that the Aβ-induced neurotoxicity observed in AD is associated with oxidative damage. Superoxide dismutase (SOD) is one of the major antioxidant metalloenzymes that converts toxic superoxide radicals (O2-) to H2O2, followed by Fenton reaction. SOD consists of three isozymes: CuZn-SOD (SOD1), which is found in the cytosol, nucleus, and intermembrane space of mitochondria; Mn-SOD (SOD2), which is localized in the mitochondrial matrix; and extracellular SOD (SOD3), which is also a complex of Cu and Zn and is found in the blood. We previously reported that Sod1-deficient (Sod1-/-) mice displayed drusen deposition, which is a typical characteristic of age-related macular degeneration, fatty liver, skin thinning, and osteoporosis. Some of these phenotypes can be alleviated by vitamin C., Although mitochondrial oxidative stress has hitherto been believed to be a potent cause of neuronal disorders, whether the damage induced by mitochondrial radicals is the main contributor to age-related diseases like AD is questionable because a systemic deficiency in SOD2 causes neonatal lethality in mice., Our previous study, which involved the use of a human amyloid precursor protein (hAPP) transgenic AD mouse model lacking Sod1 (hAPP/Sod1-/-), shed new light on the importance of cytoplasmic superoxide radicals in the pathogenesis of AD, as the hAPP/Sod1-/- mice accelerated Aβ oligomerization, memory loss, neuroinflammation, tau phosphorylation, and synaptic loss compared with the control AD mouse. As shown in Figure 1, western blotting of anti-Aβ1-16 antibody (6E10) revealed that the formation of Aβ hexamer was significantly increased in hAPP/Sod1-/- rather than hAPP/Sod1+/+. These results are in good agreement with the previous study using anti-N-terminal Aβ antibody (82E1). Intriguingly, the levels of SOD1 were significantly lower in human AD patients compared with non-AD individuals, but SOD2 and SOD3 were not. Higher levels of BACE1 were also detected in the hAPP/Sod1-/- mice, indicating that the amyloidogenic pathway had been stimulated by the presence of cytoplasmic superoxide radicals.

Figure 1. An increase of Aβ oligomer by Sod1 deletion in Alzheimer mice. (A) ELISA analysis of 82E1-specific oligomers using the TBS-soluble fraction of brains of mice (n = 5~7 per genotype) of the indicated genotypes and age. In ELISA for Aβ oligomers (Immuno Biochemical Laboratories: IBL, Gunma, Japan), the same N-terminal Aβ antibody (82E1) is used both for antigen capture and detection. In the younger ages (6−8-mo-old), the level of only Aβ oligomers was significantly increased in hAPP/Sod1-/- as compared with the hAPP/Sod1+/+ mice, but not Aβ42 or Aβ40 (ref. 15). On the other hand, older (15−17-mo-old) hAPP/Sod1-/- showed a significant elevation of Aβ oligomers as well as Aβ42 and Aβ40 (ref. 15) as compared with the hAPP/Sod1+/+ mice. These data are rearrangement of the previous work (ref. 15). (B) Distribution of Aβ aggregates by western blotting of mice (n = 4~5 per genotype) of the indicated genotypes and age. The detailed procedure was described previously (ref. 15). In brief, Tris buffered saline (TBS)-soluble fractions (2 µg/µL) were subjected to western blotting using 10–20% Tricine gel (Invitrogen) and transferred to a PVDF membrane (0.2 μm pore size, Bio-rad). Anti-Aβ antibody (6E10, 1:1,000, Signet) was used for Aβ detection. Overexposed bands corresponding to the hexamer (arrows: ~30 kDa) were used for relative quantification. left: 6−8-mo-old, right: 15−17-mo-old. *p < 0.05 vs. hAPP/Sod1+/+, mean ± s.e.m.

Figure 1. An increase of Aβ oligomer by Sod1 deletion in Alzheimer mice. (A) ELISA analysis of 82E1-specific oligomers using the TBS-soluble fraction of brains of mice (n = 5~7 per genotype) of the indicated genotypes and age. In ELISA for Aβ oligomers (Immuno Biochemical Laboratories: IBL, Gunma, Japan), the same N-terminal Aβ antibody (82E1) is used both for antigen capture and detection. In the younger ages (6−8-mo-old), the level of only Aβ oligomers was significantly increased in hAPP/Sod1-/- as compared with the hAPP/Sod1+/+ mice, but not Aβ42 or Aβ40 (ref. 15). On the other hand, older (15−17-mo-old) hAPP/Sod1-/- showed a significant elevation of Aβ oligomers as well as Aβ42 and Aβ40 (ref. 15) as compared with the hAPP/Sod1+/+ mice. These data are rearrangement of the previous work (ref. 15). (B) Distribution of Aβ aggregates by western blotting of mice (n = 4~5 per genotype) of the indicated genotypes and age. The detailed procedure was described previously (ref. 15). In brief, Tris buffered saline (TBS)-soluble fractions (2 µg/µL) were subjected to western blotting using 10–20% Tricine gel (Invitrogen) and transferred to a PVDF membrane (0.2 μm pore size, Bio-rad). Anti-Aβ antibody (6E10, 1:1,000, Signet) was used for Aβ detection. Overexposed bands corresponding to the hexamer (arrows: ~30 kDa) were used for relative quantification. left: 6−8-mo-old, right: 15−17-mo-old. *p < 0.05 vs. hAPP/Sod1+/+, mean ± s.e.m. Intracellular Aβ oligomers have recently become the focus of much AD research. It is indispensible to elucidate where Aβ oligomerizes; i.e., whether Aβ oligomerizes in the cytosol after extracellular secretion and reuptakes into cells, or whether Aβ oligomerizes in the extracellular space and reuptakes into cells. Alternatively, misfolding of Aβ in endoplasmic reticulum-Golgi may lead to oligomerization in the cytosol. Excessive free radicals in the cytosol could directly alter the conformation of intracellular Aβ; e.g., a toxic turn formation of intracellular Aβ42 were proposed by our groups., Ohyagi and coworkers revealed that intraneuronal Aβ accumulation and memory disturbance occur before extracellular Aβ deposition in mice. In the human brain, it was also reported that intracellular Aβ accumulation frequently precedes senile plaque formation. Mori, Tomiyama, and coworkers suggested that intraneuronal Aβ oligomers induce neuronal death by activating endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction. On the other hand, there have been several reports on the relationship between SOD1 protein and intracellular Aβ. As a result, it has been found that the interaction of intracellular Aβ with SOD1 decreases the activity of SOD1, and the deletion of the copper chaperone for SOD1 enhances the cytoplasmic concentration of Aβ. These findings strongly suggest the importance of cytoplasmic superoxide radicals in the intracellular Aβ-mediated AD pathologies and support our conclusion that it is an alternative therapeutic target for AD treatments. Further investigation of molecular mechanism will be required because cytoplasmic radicals may contribute to the pathogenesis of other various neurodegenerative diseases. Regarding therapies based on SOD, several AD phenotypes in mice can be improved by the direct administration of SOD, and the dietary intake of Cu stabilizes SOD1 activity. However, it should be taken into account that excessive changes in the levels of redox-active metal ions could have adverse effects due to hydroxyl radical generation. On the other hand, a number of synthetic compounds that decrease the concentrations of cellular radicals have been developed. Among them, EUK-8, a salen-manganese complex with SOD and catalase activities, and porphyrin-like compound [Mn(III) tetrakis(4-benzoic acid) porphyrin chloride, denoted as Mn-TBAP] are promising agents. Recently, some orally available compounds that protect against oxidative damage (mito-Q, and metalloporphyrin AEOL11207) were found to rescue the phenotypes of mouse models of AD and Parkinson disease, respectively. On the other hand, unexpectedly, an increase of SOD1 activity may produce H2O2, resulting in generation of hydroxyl radicals. With regard to this context, decreasing H2O2 levels by catalase or glutathione peroxidase can also be valuable to attenuate oxidative stress. Recently, apomorphine was reported to reduce the amounts of H2O2, leading to inhibition of intracellular hydroxyl radicals in AD. The combination therapy using various types of anti-oxidative stress drugs can be a promising way to delay AD. In conclusion, our research will thus not only help to advance our understanding of the molecular basis of intracellular Aβ oligomerization, but may eventually provide a starting point for the development of novel redox status modulators.
  30 in total

1.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  Monoclonal antibody against the turn of the 42-residue amyloid β-protein at positions 22 and 23.

Authors:  Kazuma Murakami; Yuko Horikoshi-Sakuraba; Nakaba Murata; Yoshihiro Noda; Yuichi Masuda; Noriaki Kinoshita; Hiroyuki Hatsuta; Shigeo Murayama; Takuji Shirasawa; Takahiko Shimizu; Kazuhiro Irie
Journal:  ACS Chem Neurosci       Date:  2010-09-28       Impact factor: 4.418

3.  Formation and stabilization model of the 42-mer Abeta radical: implications for the long-lasting oxidative stress in Alzheimer's disease.

Authors:  Kazuma Murakami; Kazuhiro Irie; Hajime Ohigashi; Hideyuki Hara; Masaya Nagao; Takahiko Shimizu; Takuji Shirasawa
Journal:  J Am Chem Soc       Date:  2005-11-02       Impact factor: 15.419

Review 4.  Amyloid beta-protein assembly and Alzheimer disease.

Authors:  Robin Roychaudhuri; Mingfeng Yang; Minako M Hoshi; David B Teplow
Journal:  J Biol Chem       Date:  2008-10-09       Impact factor: 5.157

5.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

6.  Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice.

Authors:  K Niwa; G A Carlson; C Iadecola
Journal:  J Cereb Blood Flow Metab       Date:  2000-12       Impact factor: 6.200

7.  Salen-manganese complexes are superoxide dismutase-mimics.

Authors:  M Baudry; S Etienne; A Bruce; M Palucki; E Jacobsen; B Malfroy
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

8.  Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice.

Authors:  R M Lebovitz; H Zhang; H Vogel; J Cartwright; L Dionne; N Lu; S Huang; M M Matzuk
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Meagan J McManus; Michael P Murphy; James L Franklin
Journal:  J Neurosci       Date:  2011-11-02       Impact factor: 6.167

10.  Formation of the 42-mer Amyloid β Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer's Disease.

Authors:  Kazuma Murakami; Takahiko Shimizu; Kazuhiro Irie
Journal:  J Amino Acids       Date:  2011-01-16
View more
  7 in total

1.  Preventing expression of the nicotinic receptor subunit α7 in SH-SY5Y cells with interference RNA indicates that this receptor may protect against the neurotoxicity of Aβ.

Authors:  Xiao-Lan Qi; Kai Ou-Yang; Jia-Mou Ren; Chang-Xue Wu; Yan Xiao; Yi Li; Zhi-Zhong Guan
Journal:  Neurochem Res       Date:  2013-02-21       Impact factor: 3.996

2.  The Small Molecule GAL-201 Efficiently Detoxifies Soluble Amyloid β Oligomers: New Approach towards Oral Disease-Modifying Treatment of Alzheimer's Disease.

Authors:  Hermann Russ; Michele Mazzanti; Chris Parsons; Katrin Riemann; Alexander Gebauer; Gerhard Rammes
Journal:  Int J Mol Sci       Date:  2022-05-21       Impact factor: 6.208

Review 3.  S-Nitrosylation in Alzheimer's disease.

Authors:  Qing-Fei Zhao; Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-03-25       Impact factor: 5.590

4.  A central role for dityrosine crosslinking of Amyloid-β in Alzheimer's disease.

Authors:  Youssra K Al-Hilaly; Thomas L Williams; Maris Stewart-Parker; Lenzie Ford; Eldhose Skaria; Michael Cole; William Grant Bucher; Kyle L Morris; Alaa Abdul Sada; Julian R Thorpe; Louise C Serpell
Journal:  Acta Neuropathol Commun       Date:  2013-12-18       Impact factor: 7.801

5.  Scotopic microperimetry in the early diagnosis of age-related macular degeneration: preliminary study.

Authors:  Marcella Nebbioso; Andrea Barbato; Nicola Pescosolido
Journal:  Biomed Res Int       Date:  2014-12-09       Impact factor: 3.411

Review 6.  Vitamin C, Aging and Alzheimer's Disease.

Authors:  Fiammetta Monacelli; Erica Acquarone; Chiara Giannotti; Roberta Borghi; Alessio Nencioni
Journal:  Nutrients       Date:  2017-06-27       Impact factor: 5.717

7.  L-Stepholidine rescues memory deficit and synaptic plasticity in models of Alzheimer's disease via activating dopamine D1 receptor/PKA signaling pathway.

Authors:  J-R Hao; N Sun; L Lei; X-Y Li; B Yao; K Sun; R Hu; X Zhang; X-D Shi; C Gao
Journal:  Cell Death Dis       Date:  2015-11-05       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.